EVENTIDE ASSET MANAGEMENT, LLC

13D and 13G Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
Ovid Therapeutics Inc. 13G/A Amendment 1 OVID · 690469101	OVID	690469101	6.3%	11,812,241	13G/A Amendment 1	8/14/2026 Event 6/30/2026
Eventide Asset Management, LLC			6.3%	11,812,241
Finny Kuruvilla, M.D., Ph. D.			6.3%	11,812,241
Robin C. John			6.3%	11,812,241
Immix Biopharma, Inc. 13G IMMX · 45258H106	IMMX	45258H106	5.6%	3,891,019	13G	8/14/2026 Event 6/30/2026
Eventide Asset Management, LLC			5.6%	3,891,019
Finny Kuruvilla, M.D. Ph. D.			5.6%	3,891,019
Robin C. John			5.6%	3,891,019
Xometry, Inc. 13G/A Amendment 4 XMTR · 98423F109	XMTR	98423F109	4.0%	2,151,845	13G/A Amendment 4	8/14/2026 Event 6/30/2026
Eventide Asset Management, LLC			4.0%	2,151,845
Finny Kuruvilla, M.D. Ph. D.			4.0%	2,151,845
Robin C. John			4.0%	2,151,845
Ovid Therapeutics Inc. 13G OVID · 690469101	OVID	690469101	7.3%	12,773,577	13G	5/15/2026 Event 3/31/2026
Eventide Asset Management, LLC			7.3%	12,773,577
Finny Kuruvilla, M.D., Ph. D.			7.3%	12,773,577
Robin C. John			7.3%	12,773,577
Beta Bionics, Inc. 13G/A Amendment 1 BBNX · 08659B102	BBNX	08659B102	13.4%	5,945,488	13G/A Amendment 1	5/15/2026 Event 3/31/2026
Eventide Asset Management, LLC			13.4%	5,945,488
Finny Kuruvilla, M.D., Ph. D.			13.4%	5,945,488
Robin C. John			13.4%	5,945,488
Collegium Pharmaceutical, Inc 13G/A Amendment 8 COLL · 19459J104	COLL	19459J104	4.5%	1,424,282	13G/A Amendment 8	5/15/2026 Event 3/31/2026
Eventide Asset Management, LLC			4.5%	1,424,282
Finny Kuruvilla, M.D. Ph. D.			4.5%	1,424,282
Robin C. John			4.5%	1,424,282
Inventiva S.A. 13G/A Amendment 2 F5R343107		F5R343107	4.6%	9,368,517	13G/A Amendment 2	2/13/2026 Event 12/31/2025
Eventide Asset Management, LLC			4.6%	9,368,517
Finny Kuruvilla, M.D. Ph. D.			4.6%	9,368,517
Robin C. John			4.6%	9,368,517
Evolent Health, Inc. 13G/A Amendment 3 EVH · 30050B101	EVH	30050B101	0%	1,713	13G/A Amendment 3	2/13/2026 Event 12/31/2025
Eventide Asset Management, LLC			0%	1,713
Finny Kuruvilla, M.D. Ph. D.			0%	1,713
Robin C. John			0%	1,713
Mirum Pharmaceuticals, Inc. 13G/A Amendment 4 MIRM · 604749101	MIRM	604749101	4.1%	2,093,582	13G/A Amendment 4	2/13/2026 Event 12/31/2025
Eventide Asset Management, LLC			4.1%	2,093,582
Finny Kuruvilla, M.D. Ph. D.			4.1%	2,093,582
Robin C. John			4.1%	2,093,582
Collegium Pharmaceuticals, Inc. 13G/A Amendment 7 COLL · 19459J104	COLL	19459J104	5.9%	1,876,239	13G/A Amendment 7	2/13/2026 Event 12/31/2025
Eventide Asset Management, LLC			5.9%	1,876,239
Finny Kuruvilla, M.D. Ph. D.			5.9%	1,876,239
Robin C. John			5.9%	1,876,239
Evolent Health, Inc. 13G/A Amendment 2 EVH · 30050B101	EVH	30050B101	5.4%	6,292,511	13G/A Amendment 2	11/14/2025 Event 9/30/2025
Eventide Asset Management, LLC			5.4%	6,292,511
Finny Kuruvilla, M.D. Ph. D.			5.4%	6,292,511
Robin C. John			5.4%	6,292,511
VYNE Therapeutics Inc. 13G/A Amendment 2 VYNE · 92941V308	VYNE	92941V308	0%	0	13G/A Amendment 2	11/14/2025 Event 9/30/2025
Eventide Asset Management, LLC			0%	0
Finny Kuruvilla, M.D. Ph. D.			0%	0
Robin C. John			0%	0
VYNE Therapeutics Inc. 13G/A Amendment 1 VYNE · 92941V308	VYNE	92941V308	10.0%	1,849,597	13G/A Amendment 1	8/14/2025 Event 6/30/2025
Eventide Asset Management, LLC			10.0%	1,849,597
Finny Kuruvilla, M.D. Ph. D.			10.0%	1,849,597
Robin C. John			10.0%	1,849,597
Evolent Health, Inc. 13G/A Amendment 1 EVH · 30050B101	EVH	30050B101	3.5%	4,086,852	13G/A Amendment 1	8/14/2025 Event 6/30/2025
Eventide Asset Management, LLC			3.5%	4,086,852
Finny Kuruvilla, M.D. Ph. D.			3.5%	4,086,852
Robin C. John			3.5%	4,086,852
Celldex Therapeutics, Inc. 13G/A Amendment 2 CLDX · 15117B202	CLDX	15117B202	2.0%	1,356,186	13G/A Amendment 2	8/14/2025 Event 6/30/2025
Eventide Asset Management, LLC			2.0%	1,356,186
Finny Kuruvilla, M.D. Ph. D.			2.0%	1,356,186
Robin C. John			2.0%	1,356,186
Inventiva S.A. 13G F5R343107		F5R343107	6.7%	10,118,517	13G	5/15/2025 Event 5/9/2025
Eventide Asset Management, LLC			6.7%	10,118,517
Finny Kuruvilla, M.D. Ph. D.			6.7%	10,118,517
Robin C. John			6.7%	10,118,517
Evolent Health, Inc. 13G EVH · 30050B101	EVH	30050B101	5.2%	6,077,191	13G	5/14/2025 Event 3/31/2025
Eventide Asset Management, LLC			5.2%	6,077,191
Finny Kuruvilla, M.D. Ph. D.			5.2%	6,077,191
Robin C. John			5.2%	6,077,191
Zentalis Pharmaceuticals, Inc. 13G/A Amendment 4 ZNTL · 98943L107	ZNTL	98943L107	0%	0	13G/A Amendment 4	5/14/2025 Event 3/31/2025
Eventide Asset Management, LLC			0%	0
Finny Kuruvilla, M.D. Ph. D.			0%	0
Robin C. John			0%	0
Aura Biosciences, Inc. 13G/A Amendment 3 AURA · 05153U107	AURA	05153U107	0%	0	13G/A Amendment 3	5/14/2025 Event 3/31/2025
Eventide Asset Management, LLC			0%	0
Finny Kuruvilla, M.D. Ph. D.			0%	0
Robin C. John			0%	0
Zentalis Pharmaceuticals, Inc. 13G/A Amendment 4 ZNTL · 98943L107	ZNTL	98943L107	0%	0	13G/A Amendment 4	5/13/2025 Event 3/31/2025
Eventide Asset Management, LLC			0%	0
Finny Kuruvilla, M.D. Ph. D.			0%	0
Robin C. John			0%	0
Aura Biosciences, Inc. 13G/A Amendment 3 AURA · 05153U107	AURA	05153U107	0%	0	13G/A Amendment 3	5/13/2025 Event 3/31/2025
Eventide Asset Management, LLC			0%	0
Finny Kuruvilla, M.D. Ph. D.			0%	0
Robin C. John			0%	0
Inozyme Pharma, Inc. 13G/A Amendment 2 INZY · 45790W108	INZY	45790W108	3.5%	2,220,000	13G/A Amendment 2	4/23/2025 Event 12/31/2024
Eventide Asset Management, LLC			3.5%	2,220,000
Finny Kuruvilla, M.D., Ph. D.			3.5%	2,220,000
Robin C. John			3.5%	2,220,000
Zentalis Pharmaceuticals, Inc. 13G/A Amendment 3 ZNTL · 98943L107	ZNTL	98943L107	6.3%	4,475,054	13G/A Amendment 3	2/14/2025 Event 12/31/2024
Eventide Asset Management, LLC			6.3%	4,475,054
Finny Kuruvilla, M.D., Ph. D.			6.3%	4,475,054
Robin C. John			6.3%	4,475,054
Xometry, Inc. 13G/A Amendment 3 XMTR · 98423F109	XMTR	98423F109	6.7%	3,151,897	13G/A Amendment 3	2/14/2025 Event 12/31/2024
Eventide Asset Management, LLC			6.7%	3,151,897
Finny Kuruvilla, M.D., Ph. D.			6.7%	3,151,897
Robin C. John			6.7%	3,151,897
Nektar Therapeutics 13G/A Amendment 1 NKTR · 640268108	NKTR	640268108	3.6%	6,650,000	13G/A Amendment 1	2/14/2025 Event 12/31/2024
Eventide Asset Management, LLC			3.6%	6,650,000
Finny Kuruvilla, M.D., Ph. D.			3.6%	6,650,000
Robin C. John			3.6%	6,650,000
Mirum Pharmaceuticals, Inc. 13G/A Amendment 3 MIRM · 604749101	MIRM	604749101	5.4%	2,606,938	13G/A Amendment 3	2/14/2025 Event 12/31/2024
Eventide Asset Management, LLC			5.4%	2,606,938
Finny Kuruvilla, M.D., Ph. D.			5.4%	2,606,938
Robin C. John			5.4%	2,606,938
Lexeo Therapeutics, Inc. 13G/A Amendment 3 LXEO · 52886X107	LXEO	52886X107	3.7%	1,234,834	13G/A Amendment 3	2/14/2025 Event 12/31/2024
Eventide Asset Management, LLC			3.7%	1,234,834
Finny Kuruvilla, M.D., Ph. D.			3.7%	1,234,834
Robin C. John			3.7%	1,234,834
Inozyme Pharma, Inc. 13G/A Amendment 2 INZY · 45790W108	INZY	45790W108	3.5%	2,220,000	13G/A Amendment 2	2/14/2025 Event 12/31/2024
Eventide Asset Management, LLC			3.5%	2,220,000
Finny Kuruvilla, M.D., Ph. D.			3.5%	2,220,000
Robin C. John			3.5%	2,220,000
Aura Biosciences, Inc. 13G/A Amendment 2 AURA · 05153U107	AURA	05153U107	8.2%	4,080,605	13G/A Amendment 2	2/14/2025 Event 12/31/2024
Eventide Asset Management, LLC			8.2%	4,080,605
Finny Kuruvilla, M.D. Ph. D.			8.2%	4,080,605
Robin C. John			8.2%	4,080,605
Beta Bionics, Inc. 13G BBNX · 08659B102	BBNX	08659B102	11.3%	4,857,041	13G	2/5/2025 Event 1/31/2025
Eventide Asset Management, LLC			11.3%	4,857,041
Finny Kuruvilla, M.D., Ph. D.			11.3%	4,857,041
Robin C. John			11.3%	4,857,041